Nab-paclitaxel
- Listing at source
- Listed
- Drug name
- Nab-paclitaxel
- (nab)-paclitaxel
- adebrelimab and nab paclitaxel and carboplatin
- adebrelimab nab paclitaxel oxaliplatin tegafur gimeracil oteracil potassium capsule
- adebrelimab plus nab paclitaxel and cisplatin
- adebrelimab shr 1316 nab paclitaxel cisplatin
- ak104 nab paclitaxel carboplatin
- b013 nab paclitaxel
- bevacizumab nab paclitaxel intense dose dense
- bevacizumab plus nab paclitaxel and platinum
- camrelizumab nab paclitaxel carboplatin
- camrelizumab nab paclitaxel cisplatin
- capecitabine nab paclitaxel
- carboplatin and nab paclitaxel
- carboplatin and nab paclitaxel plus atezolizumab
- carboplatin nab paclitaxel atezolizumab nai
- cisplatin and nab paclitaxel
- drug cisplatin nab paclitaxel
- drug tislelizumab cetuximab cisplatin and nab paclitaxel
- hb0025 10 mg kg plus nab paclitaxel
- hb0025 20 mg kg plus nab paclitaxel
- hrs 4508 trastuzumab nab paclitaxel
- hrs 4508 trastuzumab pertuzumab nab paclitaxel
- inetetamab pyrotinib nab paclitaxel
- lvgn3616 lvgn6051 lvgn7409 nab paclitaxel
- lvgn3616 lvgn6051 nab paclitaxel
And 48 more, listed on the interactive page.
- FDA ingredient codes (UNII)
- PF4ZJ19BNY
Related records
Trials (686)
- 9-ING-41 in Patients With Advanced Cancers
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
- A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
- A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
- A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
- A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
- A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
- A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
- A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
- A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
- A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
- A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
- A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
- A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer